🚀 VC round data is live in beta, check it out!
Straumann Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Straumann Group and similar public comparables like West Pharma, Terumo, Smith & Nephew, Fresenius Medical Care and more.
Straumann Group Overview
About Straumann Group
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
Founded
1954
HQ
Employees
11.8K
Website
Sectors
Financials (LTM)
EV
$18B
Straumann Group Financials
Straumann Group reported last 12-month revenue of $3B and EBITDA of $1B.
In the same LTM period, Straumann Group generated $2B in gross profit, $1B in EBITDA, and $492M in net income.
Revenue (LTM)
Straumann Group P&L
In the most recent fiscal year, Straumann Group reported revenue of $3B and EBITDA of $1B.
Straumann Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 31% | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $492M | XXX | $464M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 14% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Straumann Group Stock Performance
Straumann Group has current market cap of $18B, and enterprise value of $18B.
Market Cap Evolution
Straumann Group's stock price is $113.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18B | $18B | -0.4% | XXX | XXX | XXX | $2.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStraumann Group Valuation Multiples
Straumann Group trades at 5.3x EV/Revenue multiple, and 17.5x EV/EBITDA.
EV / Revenue (LTM)
Straumann Group Financial Valuation Multiples
As of March 28, 2026, Straumann Group has market cap of $18B and EV of $18B.
Equity research analysts estimate Straumann Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Straumann Group has a P/E ratio of 36.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18B | XXX | $18B | XXX | XXX | XXX |
| EV (current) | $18B | XXX | $18B | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | 17.5x | XXX | 17.5x | XXX | XXX | XXX |
| EV/EBIT | 21.3x | XXX | 21.2x | XXX | XXX | XXX |
| EV/Gross Profit | 7.6x | XXX | 8.0x | XXX | XXX | XXX |
| P/E | 36.7x | XXX | 38.9x | XXX | XXX | XXX |
| EV/FCF | 40.0x | XXX | 43.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Straumann Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Straumann Group Margins & Growth Rates
Straumann Group's revenue in the last 12 month grew by 3%.
Straumann Group's revenue per employee in the last FY averaged $0.3M.
Straumann Group's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Straumann Group's rule of X is 38% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Straumann Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | (2%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Straumann Group Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| West Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Terumo | XXX | XXX | XXX | XXX | XXX | XXX |
| Smith & Nephew | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Steris | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Straumann Group M&A Activity
Straumann Group acquired XXX companies to date.
Last acquisition by Straumann Group was on XXXXXXXX, XXXXX. Straumann Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Straumann Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStraumann Group Investment Activity
Straumann Group invested in XXX companies to date.
Straumann Group made its latest investment on XXXXXXXX, XXXXX. Straumann Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Straumann Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Straumann Group
| When was Straumann Group founded? | Straumann Group was founded in 1954. |
| Where is Straumann Group headquartered? | Straumann Group is headquartered in Switzerland. |
| How many employees does Straumann Group have? | As of today, Straumann Group has over 11K employees. |
| Is Straumann Group publicly listed? | Yes, Straumann Group is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Straumann Group? | Straumann Group trades under STMN ticker. |
| When did Straumann Group go public? | Straumann Group went public in 2001. |
| Who are competitors of Straumann Group? | Straumann Group main competitors are West Pharma, Terumo, Smith & Nephew, Fresenius Medical Care. |
| What is the current market cap of Straumann Group? | Straumann Group's current market cap is $18B. |
| What is the current revenue of Straumann Group? | Straumann Group's last 12 months revenue is $3B. |
| What is the current revenue growth of Straumann Group? | Straumann Group revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Straumann Group? | Current revenue multiple of Straumann Group is 5.3x. |
| Is Straumann Group profitable? | Yes, Straumann Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Straumann Group? | Straumann Group's last 12 months EBITDA is $1B. |
| What is Straumann Group's EBITDA margin? | Straumann Group's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Straumann Group? | Current EBITDA multiple of Straumann Group is 17.5x. |
| What is the current FCF of Straumann Group? | Straumann Group's last 12 months FCF is $449M. |
| What is Straumann Group's FCF margin? | Straumann Group's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Straumann Group? | Current FCF multiple of Straumann Group is 40.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.